Numinus

Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

• Post published:May 13, 2021
• Post category:Press Release

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

• Post published:May 11, 2021
• Post category:Press Release

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

• Post published:May 10, 2021
• Post category:Press Release

Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol

• Post published:May 4, 2021
• Post category:Press Release

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC

• Post published:April 29, 2021
• Post category:Press Release

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab

• Post published:April 26, 2021
• Post category:Press Release

Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

• Post published:March 23, 2021
• Post category:Analysis/Editorial

Numinus Announces Closing of $40-Million Bought Deal Financing

• Post published:March 19, 2021
• Post category:Press Release

Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 million

• Post published:March 15, 2021
• Post category:Press Release

Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering

• Post published:March 15, 2021
• Post category:Press Release